Discover ITT Inc.'s growth in revenue and profits, current valuation, and future outlook. Click for why a Hold rating is ...
Exelixis stock dips after Phase 3 data show modest survival gains from zanzalintinib and Tecentriq combo in colorectal cancer ...
Advocates and lawmakers introduced the Accountability for For-Profit Colleges bill package on Oct. 15, 2025, during a press ...
Summit Therapeutics is aggressively pursuing U.S. approval for ivonescimab in NSCLC, despite lacking statistically ...
EDINBURG, Pa. (MyValleyTributes) – Phillips Charles Reed, 72, of Edinburg, passed away early Saturday morning, October 18, ...
Theatre leaders have lamented slashed teacher training bursaries for creative subjects and figures revealing recruitment for ...
Most recurrent ovarian cancer cases arise in patients previously treated with PARP inhibitors making these results noteworthy ...
Exelixis, Inc. (Nasdaq: EXEL) today announced detailed results from STELLAR-303, a global phase 3 pivotal trial evaluating zanzalintinib in combination with atezolizumab (Tecentriq®) versus ...
Zacks.com on MSN
Honeywell Gears Up to Report Q3 Earnings: Is a Beat in Store?
Detailed price information for Honeywell International Inc (HON-Q) from The Globe and Mail including charting and trades.
WTM London to convene largest number of global leaders at this year’s Ministers’ Summit.
US biotech Exelixis has announced detailed results from STELLAR-303, a global Phase III pivotal trial evaluating ...
Zanzalintinib and atezolizumab improved overall survival in metastatic colorectal cancer compared to regorafenib, with a median OS of 10.9 vs 9.4 months. The combination showed progression-free ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback